Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine long acting injectable - Teva Pharmaceutical Industries

Next Previous
Drug Profile

Olanzapine long acting injectable - Teva Pharmaceutical Industries

Alternative Names: mdc-TJK; Olanzapine LAI - Teva Pharmaceutical; Olanzapine-LAI; TEV-749; TV-44749

Latest Information Update: 22 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedinCell S.A.
  • Developer MedinCell S.A.; Teva Pharmaceutical Industries
  • Class Antidepressants; Antiemetics; Antimanics; Antipsychotics; Behavioural disorder therapies; Benzodiazepines; Mood stabilisers; Piperazines; Small molecules; Thiophenes
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Schizophrenia

Most Recent Events

  • 16 Jun 2026 Teva Pharmaceutical Industries anticipates launch of Olanzapine long acting injectable for Schizophrenia in the US in fourth quarter of 2026
  • 21 May 2026 Preregistration for Schizophrenia in European Union (SC)
  • 21 May 2026 Preregistration for Schizophrenia in European Union (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top